News


  • 09 January 2013

    CoDa Therapeutics Announces Positive Results from Phase 2b Study of NEXAGON® in Chronic Venous Leg Ulcers

    CoDa Therapeutics Announces Positive Results from Phase 2b Study of NEXAGON® in Chronic Venous Leg Ulcers

    CoDa Therapeutics, Inc. today announced positive results from a Phase 2b clinical trial of NEXAGON® in patients with chronic venous leg ulcers. NEXAGON® is an easy to administer, once-a-week, topical, drug candidate being developed for the treatment of chronic wounds. It is designed to increase the incidence of wound healing compared to existing therapeutic techniques, and to heal them much faster. The company believes these results support advancing NEXAGON into Phase 3 registration trials. Venous leg ulcers are increasingly common and costly, and can be a cause of prolonged suffering for patients.

  • 07 January 2013

    Marinus Pharmaceuticals Adds $21M Series C

    Marinus Pharmaceuticals Adds $21M Series C

    Marinus Pharmaceuticals, Inc. is pleased to announce $21 million in new Series C financing from U.S. venture capital firm Domain Associates, LLC, Rusnano subsidiary RusnanoMedInvest (RMI), and co-investors.

  • 20 December 2012

    Financing Deal of the Year Nominee: Rusnano/Domain and CoDa Therapeutics

    Financing Deal of the Year Nominee: Rusnano/Domain and CoDa Therapeutics

    Wendy Diller, The IN VIVO Blog

    How about voting for a deal that turns conventional wisdom on its head.
    The biopharma industry has looked to emerging markets for near-term revenues and cost efficiencies, but not for scientific or commercial innovation. An umbrella deal between Rusnano, a five-year-old $10 billion Russian sovereign fund, and the US venture capital firm Domain Associates, announced in March, and a subsequent tie up with Domain portfolio company CoDa Therapeutics, goes some way toward erasing those misperceptions. At the same time, the partners’ tie up reflects sovereign funds’ increasingly important role in shaping the life sciences industry.

  • 20 December 2012

    Regado Biosciences, Inc. secures $51 million series e financing

    Regado Biosciences, Inc. secures $51 million series e financing

    Regado Biosciences, Inc., a privately held company leading the development of antithrombotic aptamers with active control agents, announced it has secured a landmark $51 million Series E financing. New Investor Leads Round to Fund Phase 3 Development of REG1

  • 20 December 2012

    Lithera, Inc. Completes $20.6 Million Equity Financing

    Lithera, Inc. Completes $20.6 Million Equity Financing

    Lithera, Inc. today announced investment of $20.6 million in preferred stock equity financing. The investment was led by RusnanoMedInvest (“RMI” a subsidiary of RUSNANO) made in connection with a joint investment collaboration with Domain Associates.

  • 19 December 2012

    RusnanoMedInvest and Domain Associates to invest $93m in development of three next-generation pharmaceuticals

    U.S. venture capital firm Domain Associates, Rusnano subsidiary RusnanoMedInvest (RMI) and a group of co-investors will invest a combined $93m in Marinus Pharmaceuticals, Inc., Lithera, Inc., and Regado Biosciences, Inc., all of which are developers of advanced pharmaceutical products.

  • 12 November 2012

    Fabrice Egros has been appointed COO, Pharmaceutical Director and board member of NovaMedica, a novel pharmaceutical company

    Fabrice Egros has been appointed COO, Pharmaceutical Director and board member of NovaMedica, a novel pharmaceutical company

    Fabrice Egros was appointed as COO, Pharmaceutical Director and board member of NovaMedica a novel Russian pharmaceutical company, which was established within the frameworks of the joint project between RUSNANO and the American venture fund Domain Associates.

  • 01 October 2012

    Special autumn session for the pharmaceutical business leaders

    Special autumn session for the pharmaceutical business leaders

    Vladimir Gurdus: In order to foster the development of an innovative pharmaceuticals sector in Russia, we need the support of a globally competitive cluster of venture investors in the sector here in Russia.

  • 24 July 2012

    CoDa Therapeutics Completes $49 Million Fund Raising

    CoDa Therapeutics Completes $49 Million Fund Raising

    CoDa Therapeutics, Inc. announced today that it raised an additional NZ$24.5M from Russian investment firm RusnanoMedInvest (“RMI”). This brings the company’s total Series B Round to nearly NZ$49 million following a first close late last year.

  • 24 July 2012

    Domain Associates & RUSNANO announce first joint investment

    Domain Associates & RUSNANO announce first joint investment

    Domain Associates, the Princeton, NJ- and San Diego, CA-based venture capital firm and RusnanoMedInvest (“RMI”, a subsidiary of RUSNANO) today announced their first investment under a joint agreement reached in March. The two will jointly invest nearly $40 million in San Diego, CA-based, CoDa Therapeutics, a Domain portfolio company, along with current investors GBS Ventures (Melbourne, Australia) and BioPacificVentures (Auckland, NZ).